Skip to content

Supernus Pharmaceuticals SUPN Revenue recognized that was included in deferred income at the beginning of the period

Revenue recognized that was included in deferred income at the beginning of the period at other companies

HTF
Heartflow, Inc. Common StockHTFL
$89K+166%
Paycom Software logo
Paycom SoftwarePAYC
$9M-5.3%
ePlus logo
ePlusPLUS
$24M+57.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$7.9M+204%
Rackspace Technology, Inc. logo
Rackspace Technology, Inc.RXT
$60.1M+21.2%
Q2 Holdings logo
Q2 HoldingsQTWO
$76.8M+17.4%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×